TNF and juvenile dermatomyositis: A growing literature of case reports of patients with refractory JDM has suggested the effectiveness of multiple biologics, including abatacept, tocilizumab, and tumor necrosis factor (TNF) inhibitors in addition to rituximab [4, 10, 11].